Immix Biopharma (NASDAQ:IMMX) Shares Up 7.7% – Should You Buy?

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) traded up 7.7% during trading on Tuesday . The company traded as high as $10.74 and last traded at $10.6790. 492,627 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 827,066 shares. The stock had previously closed at $9.92.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Mizuho boosted their price objective on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a report on Monday, March 30th. Wall Street Zen cut shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Citizens Jmp reissued a “market outperform” rating and issued a $23.00 target price on shares of Immix Biopharma in a research note on Friday, March 27th. Morgan Stanley started coverage on Immix Biopharma in a report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 price target for the company. Finally, HC Wainwright raised their price target on Immix Biopharma from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, March 27th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.25.

Immix Biopharma Stock Up 6.0%

The firm has a market capitalization of $572.12 million, a price-to-earnings ratio of -11.57 and a beta of 0.12. The business’s fifty day moving average is $9.39 and its 200 day moving average is $6.74.

Immix Biopharma (NASDAQ:IMMX) last released its earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Equities research analysts expect that Immix Biopharma, Inc. will post -0.79 EPS for the current year.

Institutional Investors Weigh In On Immix Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Private Advisor Group LLC boosted its position in Immix Biopharma by 9.5% during the 1st quarter. Private Advisor Group LLC now owns 34,725 shares of the company’s stock worth $316,000 after acquiring an additional 3,000 shares during the last quarter. Allworth Financial LP bought a new stake in shares of Immix Biopharma in the fourth quarter worth $30,000. Velan Capital Investment Management LP lifted its position in shares of Immix Biopharma by 40.0% in the third quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock worth $73,000 after purchasing an additional 10,000 shares in the last quarter. Mathes Company Inc. acquired a new position in Immix Biopharma during the fourth quarter worth $56,000. Finally, Tocqueville Asset Management L.P. grew its position in Immix Biopharma by 37.4% in the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock valued at $84,000 after purchasing an additional 10,950 shares in the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.